Trial Profile
Safety and efficacy of anti-von-Willebrand factor Nanobody in patients with stable angina undergoing percutaneous coronary intervention.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2011
Price :
$35
*
At a glance
- Drugs Caplacizumab (Primary)
- Indications Angina pectoris; Embolism and thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ablynx
- 07 Mar 2011 New trial record